摘要
目的探究中晚期结直肠癌患者应用氟尿嘧啶/亚叶酸钙+奥沙利铂(mFOLFOX6)方案进行治疗,分析mFOLFOX6方案的近期疗效、不良反应。方法本研究纳入2016年9月~2019年3月南京市中医院收治的45例中晚期结直肠癌患者,所有患者均采用mFOLFOX6方案化疗,将其设为观察组;筛选同期45例中晚期结直肠癌患者,予以奥沙利铂+卡培他滨(XELOX)治疗,设为对照组;比较两组近期疗效、药物不良反应;根据世界卫生组织(WHO)抗癌药物常见毒性分级标准0~Ⅳ级,观察患者药物毒副反应;检测两组外周血象变化。结果观察组客观缓解率(RR)为66.67%,对照组为57.78%,差异无统计学意义(P>0.05);观察组治疗后患者获益率为86.67%,显著高于对照组的66.67%,差异有统计学意义(P<0.05);观察组死亡率为4.44%,与对照组的6.67%比较,差异无统计学意义(P>0.05);观察组患者治疗期间呕吐恶心、白细胞减少发生率略高,但与对照组比较,差异无统计学意义(P>0.05);观察组口腔炎症、腹泻、转氨酶升高发生率略低于对照组,差异无统计学意义(P>0.05);而观察组患者手足综合征、血小板减少发生率低于对照组,差异有统计学意义(P<0.05);观察组神经毒性高于对照组,差异有统计学意义(P<0.05),但观察组11例神经毒性患者均属于Ⅰ~Ⅱ度症状,患者可耐受,不影响化疗进程。治疗后两组患者PLT、Hb、WBC外周血象指标均低于治疗前,差异有统计学意义(P<0.05);治疗后两组WBC、Hb指标比较,差异无统计学意义(P>0.05);而观察组治疗后PLT指标略高于对照组,差异有统计学意义(P<0.05)。结论对中晚期结直肠癌患者应用mFOLFOX6方案化疗,存在轻微药物毒副作用,患者可耐受,其治疗安全性良好,可作为中晚期结直肠癌治疗方案之一。
Objective To investigate the application of the modified fluorouracil or calcium folinate combined with oxaliplatin(mFOLFOX6)regimen to the treatment of the patients with advanced colorectal cancer(ACC),and to analyze the short-term efficacy and adverse reactions(ADRs)of the mFOLFOX6 regimen.Methods A total of 45 patients with ACC admitted to and treated in Nanjing Hospital of Chinese Medicine from September 2016 to March 2019 were included in the research and all treated with the chemotherapy of the mFOLFOX6 regimen,and they were taken as the observation group.Another 45 patients with ACC during the same period were selected and treated with oxaliplatin plus capecitabine(XELOX)and were taken as the control group.The short-term efficacy and ADRs to drugs were compared between the two groups.The toxic side effect among the patients was graded within the range from 0 toⅣaccording to the classification standard for common toxicity of anticancer drugs of the World Health Organization(WHO).The changes of peripheral hemogram of the two groups were detected.Results The proportion of RR in the observation group was 66.67%,while that in the control group was 57.78%,without statistically significant difference(P>0.05).After treatment,the benefit rate of the patients in the observation group was 86.67%,which was significantly higher than the 66.67%in the control group,with statistically significant difference(P<0.05).There was no statistically significant difference between the mortality rate of the observation group(4.44%)and that of the control group(6.67%)(P>0.05).The incidence of vomiting,nausea and leukopenia,among the patients in the observation group during treatment was slightly higher,but there was no statistically significant difference when compared with that in the control group(P>0.05).The incidence of oral inflammation,diarrhea and transaminase elevation,in the observation group were slightly lower than those in the control group,and the difference was statistically insignificant(P>0.05).However,the incidenc
作者
张园园
ZHANG Yuanyuan(Department of Oncology,Nanjing Hospital of Chinese Medicine,Jiangsu,Nanjing 210000,China)
出处
《中国医药科学》
2020年第22期17-20,共4页
China Medicine And Pharmacy
